Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. In July 2015, Integra LifeSciences closed the acquisition of TEI Biosciences. This company, based in Massachusetts, has developed and commercialized innovative biological devices among which SurgiMend™, a collagen matrix for soft tissue reinforcement. The acquisition of SurgiMend™ broadens Integra’s current regenerative portfolio and adds novel soft tissue reconstruction solutions.
Indicated for Plastic and Reconstructive Surgery, SurgiMend™ PRS is an acellular biologic matrix derived from fetal bovine dermis, one of the richest sources of Type III collagen available. SurgiMend™ PRS was developed to meet the specific needs of Plastic Surgeons. The collagen matrix rehydrates in a few minutes, is easy to handle and place, and is designed with fenestrations to help fluid drainage. SurgiMend™ PRS comes in multiple shapes and sizes.
Agnès Cretien - Events & Congresses Manager
email@example.com or +33-437-475-951
311 Enterprise Drive, Plainsboro Township, NJ 08536, USA